Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.73 |
| ▸ | RET | P07949 | 3/20 | 0.73 |
| ▸ | KDR | P35968 | 3/20 | 0.73 |
| ▸ | FLT3 | P36888 | 3/20 | 0.73 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.73 |
| ▸ | ABL1 | P00519 | 2/20 | 0.73 |
| ▸ | LTK | P29376 | 2/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.73 |
| ▸ | CDK7 | P50613 | 2/20 | 0.73 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.73 |
| ▸ | MST1R | Q04912 | 2/20 | 0.73 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.73 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.73 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.73 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.73 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.73 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448927 | 1.00 | NTRK1 (0.73) | NTRK1PDGFRBRETKDRFLT3 | |
| SCHEMBL5468592 | 1.00 | NTRK1 (0.73) | NTRK1PDGFRBRETKDRFLT3 | |
| SCHEMBL5469553 | 0.85 | NTRK1 (0.73) | NTRK1PDGFRBRETKDRFLT3 | |
| SCHEMBL5469550 | 0.85 | NTRK1 (0.73) | NTRK1PDGFRBRETKDRFLT3 | |
| SCHEMBL6861663 | 0.85 | NTRK1 (0.73) | NTRK1PDGFRBRETKDRFLT3 | |
| SCHEMBL14448948 | 0.85 | NTRK1 (0.73) | NTRK1PDGFRBRETKDRFLT3 | |
| SCHEMBL5465281 | 0.85 | NTRK1 (0.73) | NTRK1PDGFRBRETKDRFLT3 | |
| SCHEMBL5465283 | 0.85 | NTRK1 (0.73) | NTRK1PDGFRBRETKDRFLT3 | |
| SCHEMBL5476209 | 0.85 | FLT3 (0.73) | NTRK1PDGFRBRETKDRFLT3 | |
| SCHEMBL5476210 | 0.85 | FLT3 (0.73) | NTRK1PDGFRBRETKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| WO-2006105796-A1 | NOVEL INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2006-10-12 | — | — | WO | disclosed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | PDK3, PDK2, PDK4 | NTRK1 642/4885PDGFRB 1462/4885RET 1754/4885 |
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | NTRK1 175/4885PDGFRB 4421/4885RET 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.